La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Scilex Holding a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Scilex Holding..

Scilex Holding (NASDAQ:SCLX) Azioni, Catena delle Opzioni

SCILEX HOLDING CO

Scilex Holding

Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.

Long Ideas

News

Pre-Market Outlook

Markets

Trading Ideas

PDCO

SCLX

Scopri le tre azioni sanitarie più promettenti con un indice RSI basso: un&#39;opportunità di investimento imperdibile per settembre 2024.

3 azioni sanitarie pronte a decollare: è ora di investire?

Scilex Holding Co

WIIM

QuantaSing Group shares are trading higher. The company reported Q3 financial results.

Analyst Ratings

AMZN

CNBC Halftime Report Final Trades: Amazon, Jefferies Financial Group, e.l.f. Beauty, Ventas

Citigroup analyst Steven Enders maintains Pegasystems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEGA#NASDAQ">PEGA</a>) with a Buy and raises the price target from $116 to $131.

Price Target

PEGA

Citigroup Maintains Buy on Pegasystems, Raises Price Target to $131

GlycoMimetics's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLYC#NYSE">GLYC</a>) short percent of float has fallen 8.14% since its last report. The company recently reported that it has 1.68 million shares sold short, which is 3.16% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.71 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>GlycoMimetics Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749229230_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for GlycoMimetics has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing GlycoMimetics's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, GlycoMimetics's peer group average for short interest as a percentage of float is 2.98%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

GLYC

What Does the Market Think About GlycoMimetics?

APA's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APA#NYSE">APA</a>) short percent of float has risen 12.23% since its last report. The company recently reported that it has 40.45 million shares sold short, which is 12.76% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.35 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>APA Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749229225_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for APA has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing APA's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, APA's peer group average for short interest as a percentage of float is 8.05%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Is APA Gaining or Losing Market Support?

In the current market session, RTX Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTX#NYSE">RTX</a>) stock price is at $138.76, after a 0.22% drop. However, over the past month, the company's stock spiked by 7.85%, and in the past year, by 29.58%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is not performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2025/1749229223_0.png" alt="Past Year Chart" />

<h3>Evaluating RTX P/E in Comparison to Its Peers</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
RTX has a lower P/E than the aggregate P/E of 120.38 of the Aerospace &amp; Defense industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1749229223_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

A Look Into RTX Inc's Price Over Earnings

Albemarle's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALB#NYSE">ALB</a>) short percent of float has risen 10.43% since its last report. The company recently reported that it has 18.83 million shares sold short, which is 24.14% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.73 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Albemarle Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749229219_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Albemarle has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Albemarle's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Albemarle's peer group average for short interest as a percentage of float is 3.68%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

How Is The Market Feeling About Albemarle?

JPMorgan analyst Tami Zakaria raised the price forecast for Oshkosh Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OSK#NYSE">OSK</a>) from $92 to $106 while <a href="https://www.benzinga.com/quote/OSK/analyst-ratings" target="_blank" rel="noreferrer noopener">keeping a Neutral rating</a>.
Oshkosh (OSK)&#8217;s Investor Day occurred on Thursday, where management outlined <a href="https://www.benzinga.com/calendars/guidance" target="_blank" rel="noreferrer noopener">multi-year targets through 2028</a>.
The company expects revenue of&nbsp;$13 billion-$14 billion, adjusted EPS of&nbsp;$18.00-$22.00 <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/b45798903/oshkosh-corporation-poised-for-solid-revenue-growth-and-margin-expansion" rel="noreferrer noopener">and EBIT margin of 12%-14%</a>.
The analyst appreciated management&#8217;s increasing willingness to ramp up share repurchases as FCF conversion improves post-2025.
The feasibility of these 2028 targets (whether peak or mid-cycle) depends on the Access segment&#8217;s cycle evolution (currently in a downturn&#8217;s first year), sustained Vocational demand, and the successful ramp/mix of ICE vs. BEV in Next Generation Delivery Vehicles (NGDVs), says the analyst.
Zakaria raised the estimates, incorporating higher buybacks, leading to EPS of $9.36 (from $9.34) for 2025 and $10.87 (from $10.53) for 2026.
Overall, the analyst anticipates a modest downturn in the company&#8217;s Access Equipment sales in 2025; however, the long-term outlook is bolstered by new applications and replacement demand.
Conversely, the outlook for the company&#8217;s Defense and Vocational segments remains favorable in the near term, adds the analyst.
Price Action: OSK shares are up 0.65% at $110.35 at last check Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com//node/45755663" target="_blank" rel="noreferrer noopener">BofA Securities Stays Bullish On Caterpillar: &#8216;Surprisingly Durable&#8217; US Economy, Global Momentum</a></li>
</ul>
Photo: Shutterstock

Equities

Mid Cap

Oshkosh Investor Day Shows Path To 2028 Growth, Says JPMorgan

BRLS

Borealis Foods Shares Halted On Circuit Breaker To The Upside, Stock Now Up 84.9%

OBLG

Oblong shares are trading lower after the company announced a $7.5 million private placement agreement.

B of A Securities analyst Heather Balsky maintains PVH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PVH#NYSE">PVH</a>) with a Neutral and lowers the price target from $86 to $76.

B of A Securities Maintains Neutral on PVH, Lowers Price Target to $76

Citigroup analyst Jason Gursky maintains Planet Labs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PL#NYSE">PL</a>) with a Buy and raises the price target from $5 to $7.

Citigroup Maintains Buy on Planet Labs, Raises Price Target to $7

Drillers are packing up their gear, and investors should be paying attention, especially those invested <a href="https://www.benzinga.com/money/best-oil-stocks">in oil stocks</a>.
According to the latest Baker Hughes <a href="https://rigcount.bakerhughes.com/static-files/02aaefec-4ede-4ded-bcbb-de2c28d3e93a">report</a>, the number of <a href="https://rigcount.bakerhughes.com/intl-rig-count">international oil rigs</a> (excluding North America) fell by six rigs in May to 653, marking the lowest count in two decades outside of the COVID-19 pandemic collapse. 
That's not just a statistic, it's a potential signal of tighter oil supply ahead.
Read Also: <a href="https://www.benzinga.com/markets/25/05/45580812/trump-may-want-a-recession-market-observers-say-it-serves-his-economic-agendalower-rates-inflation-and-trade-deficit">Trump May &#8216;Want&#8217; A Recession: Market Observer Says It Serves His Economic Agenda—Lower Rates, Oil Prices, And Trade Deficit</a>
<h1 class="wp-block-heading">Fewer Rigs, Supply Squeeze, Price Boost</h1>
Fewer rigs today often mean lower production tomorrow, especially when it comes to long-lead international projects. With global demand holding steady — and OPEC+ keeping barrels off the market — this dip in drilling activity could tilt the oil market toward another supply squeeze.
For investors, this backdrop favors upstream oil producers that can operate efficiently, maintain capital discipline and generate strong cash flow even when rigs are idled.
Diamondback Energy Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FANG#NASDAQ">FANG</a>) is a textbook example. Despite plans to drop three rigs in the second quarter due to soft prices, its focus on the Permian Basin, industry-leading cost structure and resilient profitability — net income rose 7% from 2014 to 2023 despite falling oil prices — makes it a standout.
Coterra Energy Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTRA#NYSE">CTRA</a>) is also dialing back rig activity in the Permian but brings a diversified mix to the table, thanks to its Marcellus shale gas assets. That combo helps cushion the company against crude price volatility while continuing to deliver shareholder returns.
EOG Resources Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EOG#NYSE">EOG</a>) remains the shale innovator to watch. With top-tier assets in the Permian and Eagle Ford, EOG's commitment to per-well recoveries, capital efficiency and data-driven development makes it well-suited to thrive in a post-drilling-boom world.
And don't count out Occidental Petroleum Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXY#NYSE">OXY</a>) — Warren Buffett certainly hasn't. Its deep Permian presence and focus on carbon capture and enhanced oil recovery position it for both near-term gains and long-term relevance.
<h1 class="wp-block-heading">Energy ETFs Could See Renewed Investor Interest</h1>
Meanwhile, ETFs such as the Energy Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) and the SPDR S&amp;P Oil &amp; Gas Exploration &amp; Production ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOP#NYSE">XOP</a>) — which track large-cap and exploration and production energy stocks, respectively — could see renewed investor interest if crude prices move higher on supply-tightening signals.
For energy investors, this 20-year rig count low might just be the rallying cry.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/dividends/25/06/45789249/wall-streets-most-accurate-analysts-spotlight-on-3-energy-stocks-with-over-7-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Energy Stocks With Over 7% Dividend Yields</a></li>
</ul>
Photo: Shutterstock

Sector ETFs

Commodities

ETFs

CTRA

FANG

20-Year Low In Rig Counts Could Fire Up Oil Prices — And These Stocks

B of A Securities analyst Brad Sills maintains Docusign (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOCU#NASDAQ">DOCU</a>) with a Neutral and lowers the price target from $88 to $85.

DOCU

B of A Securities Maintains Neutral on Docusign, Lowers Price Target to $85

AYTU

Aytu BioPharma shares are trading higher after the company announced it entered an exclusive commercialization agreement with Fabre-Kramer for EXXUA

B of A Securities analyst Ross Gilardi maintains Oshkosh (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OSK#NYSE">OSK</a>) with a Underperform and raises the price target from $90 to $103.

B of A Securities Maintains Underperform on Oshkosh, Raises Price Target to $103

B of A Securities analyst Sara Senatore maintains Cracker Barrel Old (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBRL#NASDAQ">CBRL</a>) with a Underperform and raises the price target from $39 to $45.

CBRL

B of A Securities Maintains Underperform on Cracker Barrel Old, Raises Price Target to $45

Citigroup analyst Paul Lejuez maintains Lululemon Athletica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>) with a Neutral and lowers the price target from $325 to $270.

LULU

Citigroup Maintains Neutral on Lululemon Athletica, Lowers Price Target to $270

B of A Securities analyst Lorraine Hutchinson maintains Lululemon Athletica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>) with a Buy and lowers the price target from $400 to $370.

B of A Securities Maintains Buy on Lululemon Athletica, Lowers Price Target to $370

B of A Securities analyst Vivek Arya maintains Broadcom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) with a Buy and raises the price target from $240 to $300.

AVGO

B of A Securities Maintains Buy on Broadcom, Raises Price Target to $300

Press Releases

Scilex Holding Company Announces 1-for-35 Reverse Stock Split

Denali Capital Acquisition Corp. Announces Shareholder Approval of Extension of Deadline to Complete Business Combination

Health Care

General

Scilex Holding Company Announces Approval of a New Drug Submission (NDS) from the Health Canada's Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for ELYXYB®'s Acute Treatment of Migraine With or Without Aura in Canada

Scilex Holding Company Announces FDA Has Approved Our Request for the Orphan Drug Designation for Colchicine for the Treatment of Pericarditis

Dividends

Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from April 11, 2025 to May 2, 2025

Scilex Holding Company Regains Compliance with NASDAQ Minimum Bid Price Rule

Scilex Holding Company to Present Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the Treatment of Lumbosacral Radicular Pain (LRP) at the 27th Annual Meeting of American Society of Interventional Pain Physicians (ASIPP), May 15-17, 2025 in Orlando, FL.

Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business Combination

Scilex Holding Company Presented Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the Treatment of Lumbosacral Radicular Pain (LRP) at the 27th Annual Meeting of American Society of Interventional Pain Physicians (ASIPP), May 15-17, 2025 in Orlando, FL

Scilex Holding Company Announces Publication on GLOPERBA® Dosing Adjustments in Peer-Review Journal

DECA

SCLXW

Anebulo Pharmaceuticals, Inc. - Common Stock

Anebulo Pharmaceuticals

AN2 Therapeutics

Assertio Holdings

CalciMedica

Cingulate

Clearside Biomedical, Inc. - Common Stock

Clearside Biomedical

Context Therapeutics

Cadrenal Therapeutics, Inc. - Common Stock

Cadrenal Therapeutics

Dare Bioscience

Grace Therapeutics

IGC Pharma

Ikena Oncology

Iterum Therapeutics

Jupiter Neurosciences, Inc. - Common Stock

Jupiter Neurosciences

Lyra Therapeutics

MIRA Pharmaceuticals, Inc. - Common Stock

Mira Pharmaceuticals

NRX Pharmaceuticals

Pulmatrix

Rafael Holdings, Inc. Class B Common Stock

Rafael Holdings

Relmada Therapeutics, Inc. - Common Stock

Relmada Therapeutics

Reviva Pharmaceuticals Holdings, Inc. - Common Stock

Reviva Pharmaceuticals

SCYNEXIS

China SXT Pharmaceuticals, Inc. - Common Stock

China SXT Pharmaceuticals

Telomir Pharmaceuticals, Inc. - Common Stock

Telomir Pharmaceuticals

Verrica Pharmaceuticals Inc. - Common Stock

Verrica Pharmaceuticals

HC Wainwright & Co.

Alliance Global Partners

Rodman & Renshaw

B. Riley Securities

Semnur Pharmaceuticals, Inc., A Wholly Owned Subsidiary Of Scilex Holding Company, Announces Today The Filing Of A Registration Statement On Form S-4 by Denali Capital Acquisition Corp. With The Securities And Exchange Commission Relating To The Previously Announced Proposed Business Combination Between Semnur And Denali

Skyscrapers,Cityscape,Downtown,View,,Nashville,Skyline,Buildings.,Beautiful,Real,Estate.

Scilex Holding Company Announces Signing Of A $50 Million Registered Convertible Financing To Refinance And Restructure Existing Debt &amp; Further Strengthens Financial Profile

United,States,Bankruptcy,Court,Sign

Biotech

SRNEQ

Scilex Holding Company Announces That The U.S. Bankruptcy Court Has Extended The Lockup Period On Shares Of Scilex Dividend Stock Previously Distributed By Sorrento To Its Stockholders As A Dividend To January 31, 2025

Business,Analyst,Checking,In,Financial,Statement,For,Audit,Internal,Control

Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results for the Month Ended July 31, 2024

Hand,Of,Human,Holding,Crystal,Globe,Ball,With,Tree,For

Scilex Holding Company Announces Publication of Its Inaugural Sustainability Report

Business,Man,Sign,A,Contract,Investment,Professional,Document,Agreement.,Meeting

Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (Nasdaq: DECA) Enter into a Letter of Intent for a Proposed Business Combination

Businessmen,Making,Handshake,With,Partner,,Greeting,,Dealing,,Merger,And,Acquisition,

Scilex Holding Company Partners With New National Distributor, Endeavor Distribution LLC.

Muscular,Man,Suffering,From,Back,And,Neck,Pain.,Incorrect,Sitting

Scilex Holding Company Announces Publication In PAIN Journal Regarding Phase 3 Results Of The Pivotal Registration Trial Of SP-102 (SEMDEXA™) In Lumbosacral Radicular Pain (Sciatica)

Outside,Of,Logistics,Warehouse,With,Open,Door,,Delivery,Van,Loaded

Scilex Holding Company Announces That Many National Pharmacy Chains And Independent Pharmacies Have Begun Stocking GLOPERBA®

Interior,Of,A,Modern,Warehouse,Storage,Of,Retail,Shop,With

Scilex Holding Company Announces Stocking Of GLOPERBA® Is Underway In All Of The Wholesalers With Which Scilex Has Stocking Arrangements Throughout The U.S.

Comments

Scilex Holding

Scilex Holding (SCLX) Opzioni

Scilex Holding (NASDAQ:SCLX) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO